Gold Price Falls as Fed Rate Hike Fears and U.S.-Iran Tensions Weigh on Bullion 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
S&P Affirms Brazil’s BB Credit Rating with Stable Outlook Amid Fiscal Challenges 
China Expands Export Controls, Adds 20 Japanese Companies to Restricted List 
Japan Targets 1%+ Real Economic Growth With ¥370 Trillion Investment Plan 
US Dollar Slips After PCE Inflation Data Eases Fed Rate Hike Expectations 
China Sets 1.25% Overnight Reverse Repo Rate Below Market Expectations 
Oil Prices Rise as US-Iran Tensions Threaten Strait of Hormuz Oil Shipments 
SpaceX Eyes Starlink Mobile Phone Service to Challenge Verizon, AT&T, and T-Mobile 
Gold Prices Rise Above $4,000 as Inflation Data and Weaker Dollar Boost Demand 
Wall Street Ends Mixed as Micron Surges, Apple Drops After Price Hikes 
Asian Currencies Stay Range-Bound as Investors Eye China Data, RBNZ Outlook and U.S.-Iran Ceasefire 
Economic pessimism has set in – but there are reasons for Australians to be hopeful 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
China Factory PMI Seen Returning to Growth in June as AI Export Demand Supports Economy 
Bank Regulation Rollbacks in the U.S. and UK Could Increase Financial Risks, Study Warns 
Sanofi's Exclusive Negotiations with Clayton Dubilier & Rice
Sanofi (NASDAQ: SNY) announced on Monday that it has entered exclusive negotiations to sell a 50% controlling stake in its consumer health division, Opella, to the U.S. private equity firm Clayton Dubilier & Rice (CD&R). This strategic move reflects Sanofi's ongoing efforts to optimize its portfolio and focus on core operations.
Valuation and Investment Details
The Opella business is valued at approximately €16 billion ($17.38 billion), equating to 14 times its expected EBITDA for 2024. Additionally, the French public investment bank, Bpifrance, is anticipated to acquire a stake of around 2%, further solidifying the financial backing of this transaction.
Transaction Timeline and Approvals
The proposed sale is subject to definitive agreements and customary statutory approvals. If all goes according to plan, the transaction is expected to close by the second quarter of 2025 at the earliest, marking a significant milestone for both Sanofi and CD&R.
As the negotiations progress, stakeholders will be closely monitoring the developments surrounding this transaction, given its potential impact on Sanofi's market position and future growth strategies.
